15.15-16.45   AUDITORIUM


The Lancet/The Lancet Diabetes and Endocrinology – Research



Chairs: Lin Guo, London, UK

            Raymond Vanholder, Ghent, Belgium



Renal replacement and extracorporeal blood therapies in neonates and small children: a paradigm shift

Claudio Ronco, Vicenza, Italy


Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomized double blind placebo controlled trial

Uli Broedl, Germany


Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial
Goos Laverman, Broedl, The Netherlands


Rituximab for the treatment of childhood-onset complicated frequently relapsing/steroid-dependent nephrotic syndrome

Kazumoto Iijima, Kobe, Japan


Hemodynamic guided fluid administration for the prevention of contrast-induced Acute Kidney Injury: a randomized controlled trial

Somjot S. Brar, Los Angeles, USA


back to the timetable